Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Podzamczer

Showing results (81-90 of 107) with videos related to

Pageof 11
Sort By:
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|August 29, 1998
Brucellosis in patients infected with the human immunodeficiency virusS Moreno, J Ariza, F J Espinosa, et al.
HIV Clinical Trials|April 14, 2009
Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study)J Arrizabalaga, F Rodriguez-Alcántara, J L Castañer, et al.
HIV Clinical Trials|April 30, 2016
Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP SubstudyM Crespo, J Navarro, M Martinez-Rebollar, et al.
HIV Medicine|March 16, 2012
Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR studyM Olmo, M Saumoy, C Alonso-Villaverde, et al.
HIV Medicine|February 28, 2015
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switchJ M Tiraboschi, J A Muñoz-Moreno, M C Puertas, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 3, 1998
[Recommendations for antiretroviral treatment in 1998. AIDS Working Group of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)]S Moreno, J Arrizabalaga, J M Gatell, et al.
Medicina Clinica|May 15, 1998
[Recommendations on antiretroviral treatment. The AIDS Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology]S Moreno, J Arrizabalaga, J M Gatell, et al.
HIV Clinical Trials|July 13, 2004
Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy)A Casado, X Badia, E Consiglio, et al.
HIV Medicine|April 5, 2021
Carotid atherosclerosis in virologically suppressed HIV patients: comparison with a healthy sample and prediction by cardiovascular risk equationsM Saumoy, S Di Yacovo, S Pérez, et al.
The New England Journal of Medicine|February 15, 2001
A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98J C Lopez Bernaldo de Quiros, J M Miro, J M Peña, et al.
Pageof 11

Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|August 29, 1998
Brucellosis in patients infected with the human immunodeficiency virusS Moreno, J Ariza, F J Espinosa, et al.
HIV Clinical Trials|April 14, 2009
Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study)J Arrizabalaga, F Rodriguez-Alcántara, J L Castañer, et al.
HIV Clinical Trials|April 30, 2016
Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP SubstudyM Crespo, J Navarro, M Martinez-Rebollar, et al.
HIV Medicine|March 16, 2012
Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR studyM Olmo, M Saumoy, C Alonso-Villaverde, et al.
HIV Medicine|February 28, 2015
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switchJ M Tiraboschi, J A Muñoz-Moreno, M C Puertas, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 3, 1998
[Recommendations for antiretroviral treatment in 1998. AIDS Working Group of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)]S Moreno, J Arrizabalaga, J M Gatell, et al.
Medicina Clinica|May 15, 1998
[Recommendations on antiretroviral treatment. The AIDS Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology]S Moreno, J Arrizabalaga, J M Gatell, et al.
HIV Clinical Trials|July 13, 2004
Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy)A Casado, X Badia, E Consiglio, et al.
HIV Medicine|April 5, 2021
Carotid atherosclerosis in virologically suppressed HIV patients: comparison with a healthy sample and prediction by cardiovascular risk equationsM Saumoy, S Di Yacovo, S Pérez, et al.
The New England Journal of Medicine|February 15, 2001
A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98J C Lopez Bernaldo de Quiros, J M Miro, J M Peña, et al.
Pageof 11